Following the surge in mRNA vaccine research for COVID-19, researchers are
now seeking to apply their experience to cancer vaccines. BioNTech recently
announced a strategic partnerships with the government of UK to provide
vaccine for cancer patients. It is aimed to provide vaccination for upto
10000 patients with mRNA cancer immunotherapies by 2030.
“Our goal is to accelerate the development of immunotherapies and vaccines
using technologies we have been researching for over 20 years,” says Prof.
Ugur Sahin, CEO and cofounder of BioNTech, in a press release.“The collaboration will cover various cancer types and infectious diseases
affecting collectively hundreds of millions of people worldwide. If
successful, this collaboration has the potential to improve outcomes for
patients and provide early access to our suite of cancer immunotherapies as
well as to innovative vaccines against infectious diseases – in the U.K.
and worldwide,” he further added.
now seeking to apply their experience to cancer vaccines. BioNTech recently
announced a strategic partnerships with the government of UK to provide
vaccine for cancer patients. It is aimed to provide vaccination for upto
10000 patients with mRNA cancer immunotherapies by 2030.
“Our goal is to accelerate the development of immunotherapies and vaccines
using technologies we have been researching for over 20 years,” says Prof.
Ugur Sahin, CEO and cofounder of BioNTech, in a press release.“The collaboration will cover various cancer types and infectious diseases
affecting collectively hundreds of millions of people worldwide. If
successful, this collaboration has the potential to improve outcomes for
patients and provide early access to our suite of cancer immunotherapies as
well as to innovative vaccines against infectious diseases – in the U.K.
and worldwide,” he further added.
